Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was analyzed.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Collaborators: China-Japan Friendship Hospital; Chinese PLA General Hospital
• Treatments: Camptothecin; Cisplatin; Etoposide; Etoposide phosphate; Irinotecan

Criteria

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) of 0 to 2

• A life expectancy of at least 3 months

• Measurable lesions

• Adequate hematologic function

Exclusion Criteria:

• Infection

• Myocardial infarction within the preceding three months

• Symptomatic brain metastases or receiving radiotherapy less than 4 weeks

• Pregnancy or breast-feeding